<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000756</url>
  </required_header>
  <id_info>
    <org_study_id>DATRI 006</org_study_id>
    <secondary_id>11736</secondary_id>
    <nct_id>NCT00000756</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3</brief_title>
  <official_title>Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety, tolerance, and feasibility of adoptive immunotherapy with autologous&#xD;
      cytotoxic T-lymphocytes (CTLs) in HIV-infected patients with CD4 counts between 100 and 400;&#xD;
      to evaluate the immunologic, virologic, and clinical changes for up to 24 weeks following&#xD;
      infusion of study therapy.&#xD;
&#xD;
      Freshly isolated peripheral blood lymphocytes from HIV-1-seropositive individuals frequently&#xD;
      lyse autologous HIV-1-expressing cells or autologous cells infected with vaccinia vectors&#xD;
      encoding HIV-1-specific proteins. Administration of these cytotoxic T lymphocytes (CTLs) may&#xD;
      help prevent HIV disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Freshly isolated peripheral blood lymphocytes from HIV-1-seropositive individuals frequently&#xD;
      lyse autologous HIV-1-expressing cells or autologous cells infected with vaccinia vectors&#xD;
      encoding HIV-1-specific proteins. Administration of these cytotoxic T lymphocytes (CTLs) may&#xD;
      help prevent HIV disease progression.&#xD;
&#xD;
      AMENDED 03/28/94:&#xD;
&#xD;
      Patients are not accrued at the 25 billion CTL dose. Instead, a third cohort receives three&#xD;
      infusions of 1 billion CTL 5-8 weeks apart.&#xD;
&#xD;
      AMENDED 02/14/94:&#xD;
&#xD;
      Patients infused with 1 or 5 billion CTL will be reinfused with 1 billion CTL 6-12 months&#xD;
      later, and then followed for up to 12 weeks after the reinfusion.&#xD;
&#xD;
      ORIGINAL DESIGN:&#xD;
&#xD;
      Fifteen patients whose cells show an HIV-specific cytotoxic T lymphocyte (CTL) response are&#xD;
      infused with autologous, ex-vivo expanded CTLs at a dose of 1, 5, or 25 billion cells (five&#xD;
      patients per dose level). If one to three patients at a given dose develop acute toxicity, an&#xD;
      additional three patients will be entered at that dose. If four patients at any given dose&#xD;
      develop acute toxicity, the next lower dose will be designated as the MTD (if four patients&#xD;
      develop acute toxicity in the first cohort, the study will be terminated). Patients are&#xD;
      evaluated during infusion and at 1, 2, 4, 8, and 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">June 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphocytes, Activated</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Approved antiretroviral therapy and/or prophylactic PCP therapy, provided there was no&#xD;
             change in such therapy in the 4 weeks prior to study entry.&#xD;
&#xD;
          -  Other approved treatments for HIV-related diseases that are not known to affect&#xD;
             cellular immune response.&#xD;
&#xD;
          -  G-CSF.&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  Supportive care for acute therapy-related toxicity.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count 100 - 400 cells/mm3.&#xD;
&#xD;
          -  No current or previously documented AIDS-related opportunistic infection, malignancy,&#xD;
             or encephalopathy other than mild Kaposi's sarcoma.&#xD;
&#xD;
          -  FEV1 &gt; 70 percent, DLCO &gt; 50 percent predicted for height and age (initial infusion&#xD;
             only).&#xD;
&#xD;
          -  T cell lines with specific cytotoxicity against HIV-1.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Significant autoimmune disease.&#xD;
&#xD;
          -  Non-AIDS-associated malignancy.&#xD;
&#xD;
          -  Symptoms of cardiac disease.&#xD;
&#xD;
          -  Dyspnea on significant exertion.&#xD;
&#xD;
          -  Acute infiltrates on chest radiographs.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of significant arrhythmia, infarction, or heart failure.&#xD;
&#xD;
          -  History of a major psychiatric illness.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Systemic immunosuppressive therapy (i.e., steroids, cyclosporine, chemotherapy, or&#xD;
             alpha-interferon).&#xD;
&#xD;
          -  Therapy for acute infection, AIDS-related opportunistic infection, or malignancy.&#xD;
&#xD;
          -  Experimental AIDS therapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Potentially immunosuppressive local therapy or radiation therapy for Kaposi's sarcoma&#xD;
             within 4 weeks prior to study entry.&#xD;
&#xD;
        Current substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Lieberman</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>H Standiford</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>D Stein</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>New England Med Ctr / Tufts Univ</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, Bethel J, Kagan J. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood. 1997 Sep 15;90(6):2196-206.</citation>
    <PMID>9310470</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Lymphocytes</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Immunotherapy, Adoptive</keyword>
  <keyword>Transplantation, Autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

